



**Company Contact:  
Richard Gabriel  
CEO and President  
941 366-3400**

**-or-**

**Ron Stabiner  
The Wall Street Group, Inc.  
212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS ANCESTRY E-SYMPOSIUM TO FEATURE  
GAVIN MENZIES, NOTED HISTORIAN AND AUTHOR OF THEORY  
THAT CHINESE SAILORS REACHED AMERICA BEFORE COLUMBUS**

**SARASOTA, Fla., July 13, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that Gavin Menzies, the author of “1421 – The Year China Discovered the World,” will participate in the Ancestry e-Symposium to be held on Wednesday, July 19, beginning at 11:00 AM Eastern time at [www.ancestry.e-symposium.com](http://www.ancestry.e-symposium.com). Mr. Menzies’ book puts forth the theory that Chinese sailors discovered America before Christopher Columbus and also were the first to circumnavigate the globe.

“We are delighted that Mr. Menzies has made a commitment to our e-Symposium,” stated DNAPrint President and Chief Executive Officer Richard Gabriel. “Mr. Menzies brings a unique, historical perspective to the proceedings. After all, the Symposium is about accurately portraying human history by tracing our ancestors and coming to terms with our true origins. Mr. Menzies has put together some compelling evidence to support his theories, which challenge conventional wisdom and prompt us all to reconsider the accuracy of history. We eagerly look forward to his contributions to the Ancestry e-Symposium.”

Mr. Menzies, who is also a retired Royal Navy submarine commander, will elaborate on his theories that a Chinese armada, following the orders of Emperor Zhu Di to sail to the end of the world and back, discovered America seventy-one years before Columbus and circled the globe a hundred years before Ferdinand Magellan.

“In researching his book, Mr. Menzies went to 120 countries, visited over 900 museums and libraries, and every major seaport of the Middle Ages,” Mr. Gabriel said. “He accumulated ancient maps, star charts and linguistic evidence that all support his contention that a Chinese fleet numbering over 100 ships not only discovered America, but also Antarctica and Australia some 350 years before Captain James Cook, the legendary explorer and cartographer. In its own way, those ships set out to conquer the world, and they have conquered our imaginations as well.”

Mr. Menzies spent the first two years of his life in China. He joined the Royal Navy in 1953 and served in its submarine corps from 1959 to 1970, finishing his career as commander of the HMS Rorqual. After retiring from the Royal Navy, he returned to China and formulated the theories that would constitute his book, which was published internationally by Bantam Press and made into a two-part documentary that was aired in the United States on the Public Broadcasting System.

The Ancestry e-Symposium will be conducted entirely on the Internet. The public, genealogy professionals and other interested parties are invited to participate. To register for the free symposium, go to [www.e-symposium.com/members/signup\\_ancestry.php?price\\_group+-33](http://www.e-symposium.com/members/signup_ancestry.php?price_group+-33) and fill out the form.

(MORE)

Topics to be discussed during the symposium ([www.ancestry.e-symposium.com](http://www.ancestry.e-symposium.com)) will include the history of various peoples as determined from DNA, paleoarchaeological and linguistics evidence and the influence of genetics on health. In addition to Mr. Menzies, presenting experts are: Jason Eshleman, Senior Scientist, Trace Genetics Inc., Ancient DNA; Edward Ball, Author, *Genealogy & DNA Technology*; Ripan Malhi, Director of Research DNA, Trace Genetics, Inc., Peopling of the Americas; Jeff Long, Professor of Human Genetics and Adjunct Professor of Biostatistics University of Michigan, Raced Global Analysis of Human Genetic Structure; Toomas Kivisild, Senior Scientist, Estonian Biocentre, Genetic Variation in Asia; Tony N. Frudakis, Chief Scientific Officer, DNAPrint Genomics, Inc., Ancestry By DNA.

#### **About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com)T for information on law enforcement and consumer applications which include DNAWitness (TM), RETINOME(TM), AncestryByDNA(TM) and EuroDNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

#### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###